TheEdgeResearch
Home / Stocks / GENSF

Genus plc (GENSF)

OTC Healthcare Biotechnology
$31.07 ▲ +0.00%
Market Cap
$2.06B
Sector
Healthcare
Industry
Biotechnology
Beta
0.90
52-Wk Range
30.975-37.25
CEO
Jorgen Kokke
Country
GB
Currency
USD

Genus plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Basingstoke, HM, GB. The stock last traded at $31.07, up 0.00% on the session, giving a market capitalisation of $2.06B. On trailing twelve-month figures it carries a trailing P/E of 31.33, a net margin of 7.1%. Its beta of 0.90 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
31.33
Price / Sales
2.23
Price / Book
2.96
EV / EBITDA
14.94
Gross margin
100.1%
Operating margin
9.8%
Net margin
7.1%
Return on equity
Debt / equity
0.52
Current ratio
2.25
Dividend yield
1.5%
Payout ratio
44.4%
Company profile
Exchange
Other OTC
Employees
3,307
IPO date
2009-09-11
Headquarters
Basingstoke, HM, GB
About Genus plc

Genus plc is a global animal genetics company, with operations extending across North America, Latin America, the United Kingdom, broader Europe, the Middle East, Russia, Africa, and Asia. The firm organizes its business into three primary segments: Genus PIC, Genus ABS, and Genus Research and Development. Through its PIC brand, the company supplies breeding pigs and boar semen, enabling the production of swine with specific traits for pork processing. Furthermore, under the ABS, Genus, and Bovec labels, it provides bull semen and bovine embryos to facilitate the breeding of calves with targeted characteristics for dairy and beef output. Genus plc also extends specialized technical support to agricultural producers. Established in 1994, the company's headquarters are located in Basingstoke, United Kingdom.

Comparable companies

Genus plc is most often compared with the following Healthcare names:

BOEUFBRCTFCSPHFGRRMFGTBIFMEOBFNURPFONTTFPHMMFPPTDF
More research on GENSF
GENSF technical analysis GENSF TheEdge Score Compare against peers
Open full interactive analysis & DCF →